251 related articles for article (PubMed ID: 18567397)
1. [Natalizumab in multiple sclerosis].
Rajda C; Bencsik K; Vécsei L;
Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
[No Abstract] [Full Text] [Related]
2. Balancing risk and reward: the question of natalizumab.
Hauser SL; Johnston SC
Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
[No Abstract] [Full Text] [Related]
3. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
4. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
Major EO
N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
[No Abstract] [Full Text] [Related]
5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
6. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
7. Tysabri withdrawal calls entire class into question.
Singer E
Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500
[No Abstract] [Full Text] [Related]
8. Natalizumab: a double-edged sword?
DeAngelis LM
Ann Neurol; 2009 Sep; 66(3):262-3. PubMed ID: 19798644
[No Abstract] [Full Text] [Related]
9. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
10. [Natalizumab in multiple sclerosis: unclear patient benefits].
Schipper JP
Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Berger T; Deisenhammer F
N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16236749
[No Abstract] [Full Text] [Related]
12. Tysabri raises alarm bells on drug class.
Sheridan C
Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
[No Abstract] [Full Text] [Related]
13. Natalizumab for relapsing multiple sclerosis.
Tenser RB
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
[No Abstract] [Full Text] [Related]
14. Selective adhesion-molecule therapy and inflammatory bowel disease.
Chaudhuri A
N Engl J Med; 2006 Feb; 354(6):644-5; author reply 644-5. PubMed ID: 16467556
[No Abstract] [Full Text] [Related]
15. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Warnke C; Adams O; Kieseier BC
N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
[No Abstract] [Full Text] [Related]
16. Selective treatment of multiple sclerosis.
Ropper AH
N Engl J Med; 2006 Mar; 354(9):965-7. PubMed ID: 16510751
[No Abstract] [Full Text] [Related]
17. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
18. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
19. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for relapsing multiple sclerosis.
Jeffery DR
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
[No Abstract] [Full Text] [Related]
[Next] [New Search]
